Home › Employers › Regional Cancer Care Associates LLC
Regional Cancer Care Associates LLC: H-1B salaries and sponsorship
Regional Cancer Care Associates LLC filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $450,000.
Does Regional Cancer Care Associates LLC sponsor H-1B visas?
Regional Cancer Care Associates LLC filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Jun 17, 2024. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Physician (Hematology and Oncology) | 2 | $450,000 |
| Physician – Hematologist & Medical Oncologist | 1 | $400,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2024 | 3 | $450,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Physician – Hematologist & Medical Oncologist | $400,000 Level IV | Hackensack, NJ | Jun 17, 2024 | Sep 1, 2024 | Certified |
| Physician (Hematology and Oncology) | $450,000 | Cape May Court House, NJ | Apr 25, 2024 | Apr 25, 2024 | Certified |
| Physician (Hematology and Oncology) | $450,000 | Cape May Court House, NJ | Apr 9, 2024 | Apr 23, 2024 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).